CarolinaDSchinkeMD

PubMed

• Risk stratification in multiple myeloma: Are we there yet?
  Meera Mohan, Carolina Schinke> ;British Journal of Haematology. 2024 Apr 14
• CLO24-090: Demographics and Outcomes of Autologous Stem Cell Transplant Among IgD Multiple Myeloma Patients.
  Phillip Farmer, Clyde Bailey, Samer Al-Hadidi, Frits VanRhee, Nishanth Thalambedu, Lakshmi Yarlagadda, Sharmilan Thanendrarajan, Maurizio Zangari, Carolina Schinke> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
• A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.
  Wancheng Guo, Christopher Strouse, David Mery, Eric R Siegel, Manit N Munshi, Timothy Cody Ashby, Yan Cheng, Fumou Sun, Visanu Wanchai, Zijun Zhang, Clyde Bailey, Dais...> ;Cancers. 2024 Mar 11
• The impressive efficacy of anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple...
  Carolina Schinke> ;Chinese Clinical Oncology. 2024 Mar 6
• Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
  Meera Mohan, Jorge Monge, Nishi Shah, Danny Luan, Mark Forsberg, Vineel Bhatlapenumarthi, Metodi Balev, Anannya Patwari, Heloise Cheruvalath, Divaya Bhutani, Sharmilan...> ;Blood Cancer Journal. 2024 Mar 5
• Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study.
  Zimu Gong, Godsfavour Umoru, Jorge Monge, Nishi Shah, Ghulam Rehman Mohyuddin, Sabarinath Venniyil Radhakrishnan, Rajshekhar Chakraborty, Leo Rasche, Carolina Schinke,...> ;Blood Cancer Journal. 2024 Mar 5
• A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma.
  Sabol, H., Ashby, C., Adhikari, M., Anloague, A., Khan, S., Choudhury, S., Palmieri, M., Barnes, C., Nookaew, I., Delgado-Calle, J., Kaur, J., Schinke, C., Ambrogini, E.> ;Haematologica. 2024 Feb 22
• 1 citations
  Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency.
  Sarah Aminov, Orsi Giricz, David T Melnekoff, R Alejandro Sica, Veronika Polishchuk, Cristian Papazoglu, Bonnie Yates, Hao-Wei Wang, Srabani Sahu, Yanhua Wang, Shanish...> ;The Journal of Clinical Investigation. 2024 Feb 20
• Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy ...
  Mohan, M., Szabo, A., Patwari, A., Esselmann, J., Patel, T., Bachu, R., Rein, L., Janardan, A., Bhatlapenumarthi, V., Annyapu, E., Skoog, C., Goff, A., Hadidi, S., Rad...> ;Bone Marrow Transplantation. 2024 Feb 15
• Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
  Guo, W., Zhan, Y., Mery, D., Siegel, E., Sun, F., Cheng, Y., Ashby, T., Zhang, Z., Bailey, C., Alapat, D., Peng, H., Hadidi, S., Thanendrarajan, S., Schinke, C., Zanga...> ;Blood Cancer Journal. 2024 Feb 14
• 1 citations
  Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.
  Al Hadidi, S., Bailey, C., Panozzo, S., Cottler-Fox, M., Shaughnessy, J., Zhan, F., van Rhee, F., Thanendrarajan, S., Barlogie, B., Zangari, M., Ababneh, O., Schinke, ...> ;Blood Advances. 2024 Feb 13
• 1 citations
  Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
  Sun, F., Cheng, Y., Wanchai, V., Guo, W., Mery, D., Xu, H., Gai, D., Siegel, E., Bailey, C., Ashby, C., Al Hadidi, S., Schinke, C., Thanendrarajan, S., Ma, Y., Yi, Q.,...> ;Nature Communications. 2024 Jan 19
• Impact of Clonal Heterogeneity in Multiple Myeloma.
  Carolina Schinke, Leo Rasche, Marc S Raab, Niels Weinhold> ;Hematology/oncology Clinics of North America. 2024 Apr 1
• BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions.
  Fumou Sun, Yan Cheng, Jin-Ran Chen, Visanu Wanchai, David E Mery, Hongwei Xu, Dongzheng Gai, Samer Al Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zang...> ;The Journal of Clinical Investigation. 2024 Jan 2
• 1 citations
  High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma.
  Yan Cheng, Fumou Sun, Daisy V Alapat, Visanu Wanchai, David Mery, Wancheng Guo, Huojun Cao, Yuqi Zhu, Cody Ashby, Michael Anton Bauer, Intawat Nookaew, Eric R Siegel, ...> ;Cell Reports. Medicine. 2023 Oct 17
• 1 citations
  Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnos...
  Lucio Navarro Gordan, Carlyn Rose Tan, Robert Vescio, Jing Christine Ye, Carolina Schinke, Rohan Medhekar, Alex Z Fu, Marie-Hélène Lafeuille, Philippe Thompson-Leduc, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Jan 1
• EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression.
  Wen Ling, Sarah K Johnson, Syed J Mehdi, Daisy V Alapat, Michael Bauer, Maurizio Zangari, Carolina Schinke, Sharmilan Thanendrarajan, Frits van Rhee, Shmuel Yaccoby> ;Cancers. 2023 Sep 12
• Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States.
  Noel Estrada-Merly, Mary Eapen, Anthony E Zamora, Liliana E Pezzin, Aaron N Winn, Joyce Philip, Carolina Schinke, William R Drobyski, Larry D Anderson Jr, Anita D'Souz...> ;Bone Marrow Transplantation. 2023 Dec 1
• 9 citations
  The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
  Lindsay Hammons, Aniko Szabo, Abhishek Janardan, Vineel Bhatlapenumarthi, Evanka Annyapu, Binod Dhakal, Samer Al Hadidi, Sabarinath Venniyil Radhakrishnan, Ravi Narra,...> ;Haematologica. 2024 Mar 1
• 2 citations
  Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level.
  Lukas John, Alexandra M Poos, Alexander Brobeil, Carolina Schinke, Stefanie Huhn, Nina Prokoph, Raphael Lutz, Barbara Wagner, Maurizio Zangari, Stephan M Tirier, Jan-P...> ;Nature Communications. 2023 Aug 17
• Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines.
  Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John D Shaughnessy Jr, Fenghuang Zhan, Frits van Rhee, Samer Al Hadidi, Suhib Fahmawi> ;Journal of Cancer Policy. 2023 Sep 1
• Growth and dormancy control of myeloma cells by mesenchymal stem cells.
  Syed J Mehdi, Kalyan Ghatak, Wen Ling, Sarah K Johnson, Joshua Epstein, Intawat Nookaew, Maurizio Zangari, Carolina Schinke, Sharmilan Thanendrarajan, Frits van Rhee, ...> ;Leukemia Research. 2023 Oct 1
• 1 citations
  A gene signature can predict risk of MGUS progressing to multiple myeloma.
  Fumou Sun, Yan Cheng, Jun Ying, David Mery, Samer Al Hadidi, Visanu Wanchai, Eric R Siegel, Hongwei Xu, Dongzheng Gai, Timothy Cody Ashby, Clyde Bailey, Jin-Ran Chen, ...> ;Journal of Hematology & Oncology. 2023 Jun 29
• 4 citations
  Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor c...
  Meera Mohan, Zimu Gong, Timothy Cody Ashby, Samer Al Hadidi, Sharmilan Thanendrarajan, Carolina Schinke, Daisy Alapat, John D Shaughnessy Jr, Fenghuang Zhan, Frits van...> ;Cancer. 2023 Aug 15
• 1 citations
  The Immune Microenvironment in Multiple Myeloma Progression at a Single-cell Level.
  Carolina Schinke, Niels Weinhold> ;Hemasphere. 2023 Jun 1
• Join now to see all

Journal Articles

• Mesenchymal Stem Cells Gene Signature in High‐Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2‐Expressing Small Adipocytes  
  Bart Barlogie, Sharmilan Thanendrarajan, Carolina Schinke, British Journal of Haematology

Abstracts/Posters

• EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
  Carolina D. Schinke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker
  Carolina D. Schinke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups
  Carolina D. Schinke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Mye...
  Carolina D. Schinke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells
  Carolina D. Schinke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells
  Carolina D. Schinke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Mutational Landscape of Primary Plasma Cell Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all